Norway’s Nykode Eyes NASDAQ As Pipeline Advances
CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.
You may also be interested in...
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.